- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 8-K
------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 26, 2006
------------
Diagnostic Products Corporation
(Exact name of registrant as specified in its charter)
------------
California 1-9957 95-2802182
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
5210 Pacific Concourse Drive, Los Angeles, California 90045
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (310) 645-8200
Not Applicable
(Former name or former address, if changed since last report)
------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
- --------------------------------------------------------------------------------
Item 8.01. Other Events.
On July 26, 2006, Diagnostic Products Corporation (the "Company") issued a
press release announcing that plaintiffs in their pending shareholder derivative
action, Nicholas Weil, City of Tamarac General Employees' Pension Trust Fund and
City of Tamarac Police Officers' Pension Trust Fund, have filed a first amended
complaint in the United States District Court of the Central District of
California, Case No. CV06-00066DDP. A copy of the Company's press release is
being furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by
reference in its entirety.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit
Number Description of Exhibit
- ------ ----------------------
99.1 Press release issued by Diagnostic Products Corporation on July 26,
2006.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DIAGNOSTIC PRODUCTS CORPORATION
Dated: July 26, 2006 By: /s/ James L. Brill
------------------------------------
Name: James L. Brill
Title: Vice President, Finance and
Chief Financial Officer